Spinal muscular atrophy (SMA) is an autosomal recessive disease caused, in about 95% of SMA cases, by homozygous deletion of the survival motor neuron 1 (SMN1) gene or its conversion to the highly homologous SMN2 gene. The molecular diagnosis of SMA is usually carried out by a PCR-Restriction fragment length polymorphism (RFLP) approach. However, this approach is not useful for identification of healthy deletion carriers. TaqMan technology is one of the most reliable and widely adopted techniques for the SMN1 copy number evaluation. However, several limitations of this technique have been described. Particularly, DNA extraction methods and accurate template quantification have been shown to be critical for reliable results. In this work, we set up a reliable, highly reproducible, and easy-to-perform TaqMan technology-based protocol to obtain the SMN1 gene copy number assessment. We demonstrate that PCR amplification of both target gene and reference gene in the same reaction mix, instead of separated mixes, greatly reduces reported criticisms of simplex TaqMan technology. The multiplex real-time PCR we describe allows interlaboratory samples and data exchange, without the need to equalize the DNA isolation technique. Further, the protocol described below requires fewer replica tests than the simplex methodology does, leading to reduced overall cost for the diagnostic assay.
Introduction

S
pinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases, affecting approximately 1 in 10,000 live births (Tangsrud and Halvorsen, 1988; Czeizel and Hamula, 1989; Emery, 1991) . Childhood SMA is classically subdivided into four types based on age of onset and clinical severity (Munsat and Davies, 1992; Zerres and Rudnik-Schö neborn, 1995) , type I and IV being the most and least severe, respectively. SMA of all types is associated with mutation of both copies of the survival motor neuron 1 gene (SMN1 or SMNt; OMIM 600354; Genbank NM_000344) (Lefebvre et al., 1995) . SMN1 and its centromeric homolog (SMN2 or SMNc; OMIM 601627; GenBank NM_022875) lie within the telomeric and centromeric halves, respectively, of a large inverted repeat in chromosome region 5q13 (Lefebvre et al., 1995) . Exon 7 sequence of SMN1 differs from that of SMN2 by a single transition (840C ? T) (Bü rglen et al., 1996) . This silent translation decreases the activity in SMN2 of an exonic splicing enhancer so that less full-length transcript is generated Monani et al., 1999) . About 95% of SMA cases are caused by homozygous deletion of the SMN1 gene or its conversion to SMN2. The remaining cases are compound heterozygotes for a deletion=conversion of one SMN1 allele and a small intragenic mutation of the other allele (Wirth et al., 1999) . Since almost 5-10% of healthy people carry zero copy number of the SMN2 gene in their genome (Gerard et al., 2000) , SMN2 is not related to SMA phenotype, though its copy number may modify the severity of the disease (Lefebvre et al., 1995; Burghes, 1997; Wirth et al., 1999; Feldkö tter et al., 2002) . The frequency of healthy SMN1 deletion carriers in the general population is at least 1 in 50; thus, the detection of these subjects has a relevance in genetic counseling (Wirth et al., 1999; Ogino and Wilson, 2002; Cusin et al., 2003) . The complex genomic organization of the SMN genes at SMA locus makes difficult a reliable SMN1 quantification.
In the last few years, a way to circumvent these problems resulted from quantitative real-time PCR approaches using the SMN1 or SMN2 gene-specific primers (Cusco et al., 2002; Feldkö tter et al., 2002; Chan et al., 2004; Gó mez-Curet et al., 2007) . A further improvement to real-time PCR approaches for the SMN1 deletion carrier identification derived from the development of DNA probes with conjugated minor groove binder groups (MGB probes), more sensitive to single-base mismatches than conventional probes. For this reason, MGB probes allow differentiation between the SMN1 and SMN2 copies at the single-nucleotide exchange at position 6 in exon 7. All the methods adopted up to now are based on realtime simplex technique allowing the test gene (SMN1) and a reference gene amplification in parallel assay, but in separate reaction wells (Anhuf et al., 2003; Chan et al., 2004; Scarciolla et al., 2006) . Recently, an alternative real-time-based methodology has been described that includes an SMN2 nonextending oligonucleotide in each reaction, to avoid nonspecific interaction of primers and=or probe for the SMN1 gene (Pyatt and Prior, 2006; Gó mez-Curet et al., 2007) . Although all these technologies demonstrate a high sensitivity and specificity for the SMN gene dosage, methods of DNA extraction, sample purity, and careful DNA quantification still can influence the SMN1 copy number determination. At present, multiplex ligation-dependent probe amplification (MLPA) is a robust method for determination of the SMN1 and SMN2 copy number (Arkblad et al., 2006; Scarciolla et al., 2006; Zapletalová et al., 2007) . MLPA results are not influenced by the amount of DNA used (Schouten et al., 2002) ; however, only samples purified by the same method should be compared (www.mrc-holland.com). In the present report, we describe a simple-to-perform and highly reliable real-time multiplex protocol for SMA carrier identification. The quantitative method that we developed overcomes criticism of both different DNA isolation methods and DNA quantification because it allows the target and the reference genes to be amplified in the same reaction mix having the same DNA input.
Materials and Methods
Patients
To validate multiplex real-time assay, we used the DNA of 100 subjects previously characterized for the SMN1 gene copy number by TaqMan technology (Anhuf et al., 2003) and the comparative method of DDCt (Livak and Schmittgen, 2001 ). Sixty-six subjects out of 100 were healthy individuals carrying two copies (64 subjects) or three copies (2 subjects) of the SMN1 gene per diploid genome. The remaining 34 subjects were unrelated parents of SMA patients. The diagnosis of SMA for the affected people, demonstrated by the loss of both the SMN1 gene copies, was established by the PCR-RFLP method (Van der Steege et al., 1995) . Informed consent was obtained from all subjects.
DNA extraction
Genomic DNA was isolated from peripheral blood leukocyte by either using phenol=chloroform method (Sambrook and Russel, 2001 ) and resuspension in Tris-EDTA (TE) (TrisHCl 20 mM, EDTA 0.5 mM, pH 8.0) or using a salting-out method (Puragene Ò DNA purification system; Gentra Systems, Milan, Italy), according to the manufacturer's protocol and resuspending in DNA hydration solution (Gentra Systems). DNA concentration was determined by spectrophotometry.
Simplex real-time PCR analysis
Simplex real-time analysis was performed using TaqMan technology (ABI Prism 7300) and the comparative method of DDCt (Livak and Schmittgen, 2001) . Human serum albumin (ALB) was employed as an endogenous reference gene. Primers and TaqMan MGB 5 0 -labeled VIC probes for the SMN1 and SMN2 exon 7 locus used in this study were as previously described (Anhuf et al., 2003) . Primers and TaqMan MGB 5 0 -labeled FAM probe for the reference gene Albumin map in exon 12 and have been designed by using Primer-ExpressÔ software (v.3.0; Applied Biosystems, Milan, Italy) from GenBank sequence (NM_000477). All primers and probes were purchased from Applied Biosystems (Table 1) . DNAs were serially diluted to the final theoretical concentration of 5.0 ng=mL. The final concentration was verified by QubitÔ Fluorometer (QuantiTÔ dsDNA HS Assay Kit; Invitrogen, Milan, Italy), and it was adjusted when needed. Simplex PCR assay was carried out in triplicate. Each reaction was performed in a total volume of 13 mL containing 10.0 ng of genomic DNA, 1ÂPlatinum Ò Quantitative PCR SuperMix-UDG with ROX (Invitrogen), 300 nM of the gene-specific primers, and 100 nM of the genespecific MGB probe. PCR conditions were 2 min 508C, 10 min 958C, 40 cycles consisting of 15 s 958C, and 1 min 608C. The DNA sample of a carrier individual (one SMN1 gene copy) was used as calibrator in all amplification reactions. In these reaction conditions, no cross hybridization of the SMN1 probe to the SMN2 gene was observed; indeed, no fluorescent emission was detected with the SMN1 probe when the DNAs of five SMA patients carrying three or four copies of the SMN2 gene were tested (data not shown).
Multiplex real-time PCR analysis
Probes and primers for the multiplex reaction are the same as those used in the simplex methodology described above. DNA suspensions were serially diluted in TE to the theoretical final concentration of 5.0 ng=mL. No adjustment of the final DNA dilutions was performed; then, the amount of total DNA templates used in each multiplex assay varied from 8.36 to 14.2 ng. Multiplex reactions were performed in a total volume of 13 mL containing *8.0-14.0 ng of genomic DNA, 1ÂPlatinum Quantitative PCR SuperMix-UDG with ROX (Invitrogen), 900 nM SMN exon 7 primers, 200 nM SMN1 MGB probe, 100 nM ALB primers, and 25 nM ALB MGB probe. Reactions were carried out on an ABI Prism 7300 Sequence Detection System using 96-well MicroAmp optical plates (Applied Biosystems). PCR conditions were 2 min 508C, 10 min 958C, 40 cycles consisting of 15 s 958C, and 1 min 608C. Each DNA sample was analyzed in triplicate, and the mean of 
The nucleotides specific for the SMN1 and SMN2 genes are in bold.
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triplicates was used in each calculation. The DNA sample of the same carrier individual (one SMN1 gene copy) was used as calibrator in all amplification reactions. Although the reaction conditions optimized for the multiplex real-time PCR require higher primer and probe concentrations with respect to the simplex methodology, we verified that the SMN1-specific MGB probe failed to detect amplification using DNAs from SMA patients with different copy number of the SMN2 gene (see ''Simplex real-time PCR analysis'').
Statistical analysis
The reliability of the SMN1 copy number assay was measured by determining the coefficient of variation (CV). The CV for each sample was calculated by dividing the standard deviation (SD) of three repeated assays in a given subject by the average SMN1 copy number for that subject. The mean CV for SMN1 deletion carriers and control groups was calculated by dividing the SD from the average copy number measured in each group by the average SMN1 copy number measured for that group. R 2 was calculated considering the measured SMN1 copy number of three repeated assays in a given subject.
Results
In our laboratory, the SMN1 gene copy number for people at risk to be deletion carrier is usually assessed by real-time PCR adopting the well-established TaqMan technology (Anhuf et al., 2003) and the comparative method of DDCt (Livak and Schmittgen, 2001 ). Albumin is employed as endogenous control gene (see Materials and Methods section). The protocol we adopt for the simplex real-time PCR allows specific SMN1 or SMN2 exon 7 detection, without any cross hybridizations of the SMN1-specific MGB probe with the SMN2 copy or vice versa. Indeed, DNA samples isolated from five patients with zero copies of the SMN1 gene and three or four copies of the SMN2 gene failed to detect amplification utilizing the SMN1-specific MGB probe. Likewise, DNA samples isolated from four healthy subjects with zero copies of the SMN2 gene and two copies of the SMN1 gene failed to detect amplification utilizing the SMN2-specific MGB probe (data not shown). Although we are confident with the simplex technology, we verify the same technical limitations encountered by others such as DNA extraction methods and accurate DNA template quantification. Indeed, to guarantee reliable results for the SMN1 gene quantification by the simplex methodology adopted, the DNA extraction methodology is uniform and DNA concentration is accurately quantitated. However, the overall performance for testing the SMN1 copy number can be improved amplifying, in the same reaction, the test gene (SMN1) and the reference gene (ALB). We set up a multiplex real-time PCR for SMN1 exon 7 as target locus and ALB exon 12 as reference locus. TaqMan MGB probes and primers used in this study are described in Table 1 . To optimize the highest intensity and specificity of each reporter fluorescent signal, we performed separate multiplexed preruns, with different primer and probe concentrations. Since the optimized conditions required higher primer and probe concentrations for the multiplex with respect to the simplex real-time PCR, we had to verify the occurrence of any cross hybridization of the SMN1-specific MGB probe with the SMN2 gene. The SMN1-specific MGB probe failed to detect nonspecific signal, in the new reaction conditions too. Afterward, we compared the reproducibility of the SMN1 gene quantification adopting simplex and multiplex methodology in three independent PCR reactions of the same DNA samples (Table 2 ; Fig. 1 ). Both methodologies used the same DNA from an obligate SMN1 deletion carrier as calibrator sample. DNA of four deletion carriers and four control subjects previously identified were utilized. As shown in Table 2 , DNA The mean measured SMN1 copy number, range, SD, CV%, and statistical index of R 2 are summarized for simplex and multiplex real-time PCR, respectively. Methods adopted for DNA isolation are reported.
a A common carrier=calibrator DNA isolated by phenol=chloroform technique.
samples were isolated by adopting different methods: four DNAs, two carriers (n.1 and n.2) and two controls (n.3 and n.4), and the carrier=calibrator DNA (n.5) were isolated from blood samples by phenol=chloroform procedure (Sambrook and Russel, 2001) , while four DNAs, two carriers (n.6 and n.7) and two controls (n.8 and n.9), were isolated by salting-out procedure (Gentra kit). As shown in Table 2 , the CV% is lower and the R 2 value is higher in the multiplex compared to the simplex methodology, regardless of techniques adopted for testing and reference of DNA samples in isolation. For a better overview of the simplex and multiplex Q-PCR comparison, the results obtained are plotted in Figure 1 . Testing DNAs obtained by phenol=chloroform extraction method are plotted in Figure 1A , while testing DNAs obtained by salting-out method are plotted in Figure 1B . These results suggest the need of fewer multiplex than simplex replica tests to be confident with the results achieved.
A total of 100 DNA samples of the known SMN1 copy numbers were used to validate the detection of SMN1 exon 7 heterozygous deletion by the multiplex real-time assay (Table  3) . Thirty-four of these DNAs were isolated from parents of SMA-affected people who were assumed to be obligate the SMN1 deletion carriers. As shown in Table 3 , the results in 33 out of 34 carriers confirmed the carrier status (mean measured copy number 0.98). One out of 34 of these obligate deletion carriers resulted with two SMN1 gene copies (mean measured copy number 2.25), suggesting to be a 2=0 genotype (two copies of the SMN1 gene both in one chromosome). Two out of 66 control DNA samples carried three SMN1 copies (mean measured copy number 3.15). As shown in Table 3 , there is no overlap between the range for SMN1 copy numbers in deletion carriers and controls. Further, we verified that with our multiplex assay reliable results do not require a precise determination of DNA concentration, ranging from 8.36 to 14.2 ng per well. The correct identification of the 33=34 deletion carriers gives this technology an analytic sensitivity of 97.06%, and the correct exclusion of the 66 normal samples gives this strategy an analytic specificity of 100%.
Discussion
In this study, we set up a highly sensitive multiplex real-time PCR approach for the correct identification of the SMN1 deletion carrier status. Quantitative multiplex real-time PCR is For controls and heterozygous carriers of the SMN1 deletion, the SMN1 gene copy number and the mean, range, SD, and CV% are shown.
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already successful for gene dosage assessment of other human diseases, such as PLP1 gene duplication involved in the Pelizaeus-Merzbacher disease (Mikešová et al., 2006) . We demonstrate that the PCR amplification of both target gene and reference gene in the same reaction mix, instead of separated mixes, greatly reduces interassay variations for DNA replica tests as well as for different DNA templates (Table 2 ; Fig. 1A,  B) . Indeed, the CV (CV% in Table 2 ) is lower while the R 2 is higher in the multiplex compared to the simplex methodology, especially when testing and reference DNA samples were isolated following different techniques. The multiplex real-time assay proposed confirmed the carrier status in 33 out of 34 parents of affected subjects (Table 3) . One out of 34 of these obligate deletion carriers resulted with two copies of the SMN1 gene, suggesting a 2=0 genotype (two copies of the SMN1 gene-both in one chromosome). Two copies of the SMN1 gene in one chromosome, depicting a 2=1 genotype, were also identified in 2 out of 66 DNA samples isolated from no deletion carrier subjects. As shown in Table 3 , there is no overlap between the range for the SMN1 copy numbers in deletion carriers and controls, thereby allowing a clear differentiation between the SMN1 deletion carriers and noncarrier subjects. The technology we proposed has an analytic sensitivity of 97.06%, due to 2=0 unidentifiable genotype, and an analytic specificity of 100%. Many advantages arise from the method we propose. First, multiplex real-time PCR will improve interlaboratory samples and data exchange, without the need to equalize the DNA isolation technique. Second, it provides reliable results also when the testing DNA input and calibrator DNA input are not exactly the same. Finally, the overall cost of the test can influence the extent of people who take advantage of it. The multiplex assay that we propose at least halves the cost per individual assessment for the carrier status, allowing a greater number of parents and relatives of patients with SMA to receive a correct assessment of recurrence risk.
